PNEUMOCOCCAL CONJUGATE VACCINE SCHEDULES SHAPE SEROTYPE-SPECIFIC MEMORY B-CELL RESPONSES

Read the full article See related articles

Listed in

This article is not in any list yet, why not save it to one of your lists.
Log in to save this article

Abstract

Reduced-dose pneumococcal conjugate vaccine (PCV) schedules (‘1+1’; one primary and one booster) are now endorsed by the World Health Organisation under specific circumstances. Serotype-specific memory B cells (B MEM ) are a marker of long-term protection but data from infant reduced-dose trials remain limited. As part of a randomised controlled trial in Vietnamese infants, we characterised serotype-specific B MEM responses in randomised subsets (N=50 per vaccine group per timepoint) following 0+1 (at 12 months of age) or 1+1 (2 and 12 months of age) schedules of PCV10 or PCV13, using a multimer spectral flow cytometry approach. Blood samples were collected at 12 months of age (baseline) and at day 7 and day 28 post-vaccination.

A one or two dose schedule of either PCV induced robust serotype-specific B MEM responses at day 7 and day 28 for most serotypes. PCV13 generated earlier and higher B MEM responses than PCV10, while 1+1 schedules for either PCV produced higher B MEM responses than the 0+1 schedules at day 7. By day 28, these differences between the 0+1 and 1+1 schedules were no longer apparent. Notably, B MEM responses for serotypes 6B and 23F were detectable even in infants who did not achieve protective levels of serotype-specific IgG ≥0.35 µg/mL. PCV13 generated higher plasmablast and plasma cell responses by day 7, and higher cTfh responses by day 28, compared to PCV10.

These findings show that 1+1 schedules of PCV10 or PCV13 induce robust B MEM responses, with important implications for the evaluation of PCVs and understanding long-term protection.

Article activity feed